Navigation Links
Existing medicines show promise for treating stomach and bowel cancer
Date:2/4/2014

Stomach and bowel cancer, two of the most common cancers worldwide, could be treated with a class of medicines that are currently used to treat a blood disorder, a Melbourne research team has discovered.

The finding, in preclinical models, that medicines called 'JAK inhibitors' reduce the growth of inflammation-associated stomach and bowel cancer provides the first evidence supporting their use in treating these cancers.

JAK inhibitors are currently used to treat the cancer-like condition myelofibrosis, and are being investigated in clinical trials for the treatment of conditions including leukaemia, lymphoma, lupus and rheumatoid arthritis.

Dr Emma Stuart, Dr Tracy Putoczki and Associate Professor Matthias Ernst from the Walter and Eliza Hall Institute made the discovery with colleagues while at the Melbourne-Parkville Branch of the Ludwig Institute for Cancer Research. Associate Professor Ernst is also currently a Ludwig Member. Their findings have been published in the journal Molecular Cancer Therapeutics.

Stuart said the discovery stemmed from the research team's long interest in the links between inflammation and cancers of the digestive tract. "Recently we have begun to unravel the complex signaling that occurs in inflamed tissues, such as when a person has a stomach ulcer or suffers from inflammatory bowel disease, and how this drives cancer development," she said.

"By understanding the molecules that are involved in promoting the survival and growth of cancer cells, we have been able to identify which of these molecules can be targeted with potential anti-cancer treatments. In this case, we determined that proteins called JAKs are involved in cancer formation in the stomach and bowel. It was exciting to discover that when JAKs were blocked with existing medications (JAK inhibitors), bowel and stomach cancer growth in experimental models was slowed, and many of the cancer cells were killed," Stuart said.

Ernst said the findings were significant as JAK inhibitors were already available and had shown success in clinical trials, particularly for treating cancer-like blood conditions.

"Our team's research has uncovered several proteins that could be valuable targets in treating cancers of the digestive tract," he said. "The reason this discovery is particularly exciting is clinical trials have already shown that JAK proteins can be safely and successfully inhibited in patients. We hope this will expedite bringing our research to possible clinical trials that may improve the outlook for people with stomach and bowel cancer," Ernst said.


'/>"/>

Contact: Vanessa Solomon
solomon@wehi.edu.au
61-393-452-971
Walter and Eliza Hall Institute

Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research


Source:Eurekalert  

Related medicine news :

1. India Network International Visitor Health Insurance Announces Higher Pre-existing Coverage Limits for Visitors of All Ages
2. OnPage Pager Replacement and Priority Messaging Software can Now be Activated via Your Existing Communication Terminals
3. No Medical Exam Life Insurance Is A Simple Method Of Getting Coverage For People Who Have A Pre-Existing Medical Condition
4. Life Insurance Without Exam Is Available For People Who Have A Pre-Existing Medical Condition
5. India Network Visitor Health Insurance Plan Offers New Options for Preexisting Conditions Coverage for All Ages, 0 to 99 Years Old
6. Plaintiffs in 77 Risperdal Gynecomastia Lawsuits File Motion to Force J&J to Comply with Existing Settlement Agreement, Reviewed By Wright & Schulte LLC
7. Curb Premature Wrinkling or Reduce Existing Wrinkles With Sublime Beauty Products, Including a New Hyaluronic Serum on Sale This Week
8. India Network Foundation Seeks Community Input on Pre-Existing Conditions Visitor Health Insurance Programs for 2014
9. Obamacare Changes Network to Medicare from United Health Care for All Policy Holders of Pre-existing Health Insurance Plan
10. simplifyMD’s EHR Software Selected to Replace Existing Technology at Celebration Orthopaedic & Sports Medicine Institute
11. IMG Add Moratorium Option, Increasing Likelihood of Pre-existing Conditions Cover for Globalsurance Clients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Existing medicines show promise for treating stomach and bowel cancer
(Date:6/22/2017)... ... ... Branches, Inc. has been partnering with The Miami Foundation for over 9 ... focused on providing opportunity to low-income families and breaking the cycle of generational poverty. ... to support its , Climb to College & Career initiative which focuses on postsecondary ...
(Date:6/22/2017)... ... ... its pervasiveness, many physicians are unfamiliar with how best to treat of NeuP, partly ... a timely review has been published in the Journal of Pain Research ... preclinical scientists on its diagnosis and choice of treatment. , The review, titled “ ...
(Date:6/20/2017)... , ... June 20, 2017 , ... ... announced today that Claritas Capital, a Nashville-based private equity firm, has invested $3.35 ... expansion plans for some time, and Claritas Capital offers the smart money, speed ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... has published a new eBook titled “ 5 Questions to Ask Before Entering ... Analyst on the Genetic Test Evaluation (GTE) team, the book explores the various ...
(Date:6/20/2017)... ... , ... AMC Health , the leading provider of proven real-time virtual ... Similar to its approach in demonstrating positive outcomes in the healthcare market, AMC Health ... value of eVisits to support virtual studies. , In a study concluded ...
Breaking Medicine News(10 mins):
(Date:6/20/2017)... LAGUNA HILLS, Calif. , June 20, ... data that validate the use of MMprofiler with SKY92, ... multiple myeloma (MM). In a poster presentation at the ... (EHA) in Madrid, Spain , SkylineDx ... identifying high-risk elderly patients. In a ...
(Date:6/20/2017)... , June 19, 2017  Hill-Rom Holdings, Inc. (NYSE: ... call and webcast on Friday, July 28, 2017, beginning at ... Call Audio Only Dial-in information: To participate in the conference ... dial into the call at least 10 minutes prior to ... is 34090339.  Webcast: ...
(Date:6/19/2017)... -- Researchers from DRUGSCAN ® and INC Research ® ... complimentary webinar titled, "Untangling methods to tamper with opioid ... on Wednesday June 28, 2017 from 12:00 PM to ... feature interviews with recreational and dependent prescription opioid abusers ... use to prepare opioid tablets for routes of administration ...
Breaking Medicine Technology: